RT Journal Article
SR Electronic
A1 Shuman, Jill
T1 ATL1103 Effective in Reducing IGF-1 Levels in Patients With Acromegaly
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 4
SP 14
OP 15
DO 10.1177/1559897715583822
UL http://mdc.sagepub.com/content/15/4/14.2.abstract
AB Acromegaly is caused by an overproduction of growth hormone, and subsequently, insulin-like growth factor-I. ALT1103 is second-generation drug that reduces expression of the growth hormone receptor. In a phase 2 trial, patients with acromegaly who received 400 mg of ALT1103 showed a significant reduction in insulin-like growth factor-I at 14 weeks.